keyword
MENU ▼
Read by QxMD icon Read
search

Cabergolin

keyword
https://www.readbyqxmd.com/read/27908214/pregnancy-and-tumor-outcomes-in-infertile-women-with-macroprolactinoma-on-cabergoline-therapy
#1
Ashu Rastogi, Sanjay K Bhadada, Anil Bhansali
Hyperprolactinemia and prolactinomas cause infertility in significant number of women. But, pregnancy may lead to post-partum remission of hyperprolactinemia. The data on pregnancy and tumor outcome in women with macroprolactinoma conceiving on Cabergoline (CAB) therapy is increasing but still less than with Bromocriptine. We studied the incidence of fetal malformations, hyperprolactinemia and tumor course after gestation in infertile women harboring macroprolactinoma, who conceived on CAB therapy during the year 2005-2015...
December 2, 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27901279/dopamine-agonists-for-preventing-ovarian-hyperstimulation-syndrome
#2
REVIEW
Huilin Tang, Selma Mourad, Suo-Di Zhai, Roger J Hart
BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is a potentially serious complication of ovarian stimulation in assisted reproduction technology (ART). It is characterised by enlarged ovaries and an acute fluid shift from the intravascular space to the third space, resulting in bloating, increased risk of venous thromboembolism and decreased organ perfusion. Most cases are mild, but forms of moderate or severe OHSS appear in 3% to 8% of in vitro fertilisation (IVF) cycles. The dopamine agonist cabergoline was introduced as a secondary prevention intervention for OHSS in women at high risk of OHSS undergoing ART treatment...
November 30, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27900635/somatostatin-and-dopamine-receptor-regulation-of-pituitary-somatotroph-adenomas
#3
REVIEW
Anat Ben-Shlomo, Ning-Ai Liu, Shlomo Melmed
Somatostatin and dopamine receptors are expressed in normal and tumoral somatotroph cells. Upon receptor stimulation, somatostatin and the somatostatin receptor ligands octreotide, lanreotide, and pasireotide, and to a lesser extent, dopamine and the dopamine analogs bromocriptine and cabergoline, suppress growth hormone (GH) secretion from a GH-secreting pituitary somatotroph adenoma. Somatostatin and dopamine receptors are Gαi-protein coupled that inhibit adenylate cyclase activity and cAMP production and reduce intracellular calcium concentration and calcium flux oscillations...
November 29, 2016: Pituitary
https://www.readbyqxmd.com/read/27897674/dopamine-alters-the-fidelity-of-working-memory-representations-according-to-attentional-demands
#4
Sean James Fallon, Nahid Zokaei, Agnes Norbury, Sanjay G Manohar, Masud Husain
Capacity limitations in working memory (WM) necessitate the need to effectively control its contents. Here, we examined the effect of cabergoline, a dopamine D2 receptor agonist, on WM using a continuous report paradigm that allowed us to assess the fidelity with which items are stored. We assessed recall performance under three different gating conditions: remembering only one item, being cued to remember one target among distractors, and having to remember all items. Cabergoline had differential effects on recall performance according to whether distractors had to be ignored and whether mnemonic resources could be deployed exclusively to the target...
November 29, 2016: Journal of Cognitive Neuroscience
https://www.readbyqxmd.com/read/27856776/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#5
John W Winkelman, Melissa J Armstrong, Richard P Allen, K Ray Chaudhuri, William Ondo, Claudia Trenkwalder, Phyllis C Zee, Gary S Gronseth, David Gloss, Theresa Zesiewicz
OBJECTIVE: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. METHODS: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. RESULTS AND RECOMMENDATIONS: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B)...
November 16, 2016: Neurology
https://www.readbyqxmd.com/read/27855233/a-macroprolactinoma-becoming-resistant-to-cabergoline-and-developing-atypical-pathology
#6
Emilia Sbardella, George Farah, Ahmed Fathelrahman, Simon Cudlip, Olaf Ansorge, Niki Karavitaki, Ashley B Grossman
: Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27854004/erratum-to-prospective-long-term-study-of-the-effect-of-cabergoline-on-valvular-status-in-patients-with-prolactinoma-and-idiopathic-hyperprolactinemia
#7
Laurent Vroonen, Patrizio Lancellotti, Monica Tomé Garcia, Raluca Dulgheru, Matilde Rubio-Almanza, Ibrahima Maiga, Julien Magne, Patrick Petrossians, Renata Auriemma, Adrian F Daly, Albert Beckers
No abstract text is available yet for this article.
November 16, 2016: Endocrine
https://www.readbyqxmd.com/read/27849387/serum-levels-of-f%C3%A4-broblast-growth-factor-23-osteoproteger%C3%A4-n-and-receptor-act%C3%A4-vator-of-nuclear-factor-kappa-b-l%C3%A4-gand-rankl-%C3%A4-n-pat%C3%A4-ents-w%C3%A4-h-prolact%C3%A4-noma
#8
Muyesser Sayki Arslan, Mustafa Sahin, Melia Karakose, Esra Tutal, Oya Topaloglu, Bekir Ucan, Taner Demirci, Mustafa Caliskan, Seyda Sahingol, Mustafa Ozbek, Erman Cakal
PURPOSE: The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear kB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to the pituitary prolactinoma. METHODS: 46 premenopausal female patients with prolactinoma and age and sex matched healthy controls (Group 3, n=20) were recruited to this cross sectional study. Prolactinoma patients were divided into two groups as patients newly diagnosed (Group 1, n=26), and under cabergoline treatment (Group 2, n=20)...
November 16, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27848079/cabergoline-and-prolactinomas-lack-of-association-between-drd2-polymorphisms-and-response-to-treatment
#9
Cbf Bueno, E B Trarbach, M D Bronstein, A Glezer
BACKGROUND: About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable effectiveness of cabergoline (CAB). OBJECTIVE: To assess the influence of DRD2 polymorphisms in responsiveness of CAB treatment in patients with prolactinoma...
November 15, 2016: Pituitary
https://www.readbyqxmd.com/read/27796464/ergot-and-non-ergot-dopamine-agonists-and-heart-failure-in-patients-with-parkinson-s-disease
#10
François Montastruc, Florence Moulis, Mélanie Araujo, Leila Chebane, Olivier Rascol, Jean-Louis Montastruc
PURPOSE: Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years. METHODS: A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016...
October 27, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27783196/management-of-prolactinomas-a-survey-of-physicians-from-the-middle-east-and-north-africa
#11
Salem A Beshyah, Ibrahim H Sherif, Farida Chentli, Amir Hamrahian, Aly B Khalil, Hussein Raef, Mohamed El-Fikki, Selim Jambart
BACKGROUND: Prolactinomas are the commonest functional tumors of the pituitary gland. There are still controversies regarding medical therapy in specific clinical situations. Patients may be managed by different specialists in the Middle East and North Africa (MENA) region and no data exist on patterns of clinical management. OBJECTIVES: To ascertain the diagnostic and therapeutic approaches to prolactinomas among relevant professionals from the MENA region. METHODS: An online survey of a large sample of physicians was conducted...
October 25, 2016: Pituitary
https://www.readbyqxmd.com/read/27766549/daily-life-reflections-of-acromegaly-guidelines
#12
T Apaydin, H M Ozkaya, F E Keskin, O A Haliloglu, K Karababa, S Erdem, P Kadioglu
PURPOSE: To determine the differences in acromegaly diagnosis, treatment, and follow-up among Turkish endocrinologists, and to investigate how the published guidelines are applied in clinical practice. METHODS: The questionnaire was formatted as an electronic survey, conducted between November and December 2015, and sent weekly for 6 weeks via e-mail to 528 endocrinologists in Turkey. RESULTS: The questionnaire was answered by 37.4 % of endocrinologists...
October 20, 2016: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/27749534/effects-of-cabergoline-on-blood-glucose-levels-in-type-2-diabetic-patients-a-double-blind-controlled-clinical-trial
#13
Adele Bahar, Zahra Kashi, Ezzatossadat Daneshpour, Ozra Akha, Shahram Ala
BACKGROUND: Cabergoline is a long-acting agonist of dopamine, which has a high affinity to dopamine receptors (type 2). Treatment using a dopaminergic agonist reduces hypothalamic stimulation that increases during liver gluconeogenesis, lipids synthesis, and insulin resistance. Our aim was to evaluate the effects of cabergoline on blood glucose levels in patients with type 2 diabetes mellitus (DM). METHODS: This study was a double-blind, controlled clinical trial in patients with type 2 DM...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27748657/myocardial-recovery-in-peripartum-cardiomyopathy-after-hyperprolactinemia-treatment-on-bivad
#14
Dominik Wiedemann, Thomas Schlöglhofer, Julia Riebandt, Markus Neuner, Edda Tschernko, Heinrich Schima, Daniel Zimpfer
Peripartum cardiomyopathy requiring mechanical ciruculatory support is rare however it is a lifethreatening disease with recovery rates poorer than expected. Herein we describe a case of successfull recovery of a patient with peripartum cardiomyopathy. Implantation of a biventricular ventricular assist device was performed, additonally the patient's hyperprolactinemia was treated with Cabergoline resulting in a fast complete restoration of ventricular function.
September 22, 2016: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
https://www.readbyqxmd.com/read/27737325/experience-with-pegvisomant-treatment-in-acromegaly-in-a-single-brazilian-tertiary-reference-center-efficacy-safety-and-predictors-of-response
#15
Leandro Kasuki, Evelyn de Oliveira Machado, Liana Lumi Ogino, Maria Caroline Alves Coelho, Cintia Marques Dos Santos Silva, Luiz Eduardo Armondi Wildemberg, Carlos Henrique Azeredo Lima, Mônica R Gadelha
Objective: To describe the safety and efficacy of pegvisomant therapy and the predictors of treatment response in acromegaly patients at a single tertiary reference center in Brazil. Materials and methods: We retrospectively reviewed the clinical, hormonal and radiological data of acromegaly patients treated with pegvisomant in our center. We also evaluated the presence of the d3 isoform of the growth hormone receptor (d3GHR). Results: Twenty-seven patients were included (17 women)...
October 2016: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27734694/-current-and-future-therapy-of-acromegaly
#16
Václav Hána
Acromegaly is a rare disease caused by overproduction of growth hormone, which significantly worsens quality of life and increases morbidity and mortality of patients. Modern specialized surgery, radiosurgery, radiotherapy and pharmacotherapy substantially improved therapeutical possibilities and the perspective of patients. Current thera-peutic modalities enable to create individually tailored therapy for the specific patient and suppress the acromegalic activity. Novel forms of currently used active substances and even conceptually new forms of pharmacotherapy are under preparation and testing (eg...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27709470/prospective-long-term-study-of-the-effect-of-cabergoline-on-valvular-status-in-patients-with-prolactinoma-and-idiopathic-hyperprolactinemia
#17
Laurent Vroonen, Patrizio Lancellotti, Monica Tomé Garcia, Raluca Dulgheru, Matilde Almanza, Ibrahima Maiga, Julien Magne, Patrick Petrossians, Renata Auriemma, Adrian F Daly, Albert Beckers
Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia...
October 5, 2016: Endocrine
https://www.readbyqxmd.com/read/27689434/cabergoline-or-bromocriptine-for-prolactinoma
#18
Nicolás Triantafilo, Victoria Castro-Gutiérrez, Gabriel Rada
Cabergoline and bromocriptine are among the most commonly used drugs to treat prolactinoma. Cabergoline is a long-acting dopamine receptor agonist which might offer advantages over bromocriptine. However, it is not clear if this translates into clinical benefits. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified two systematic reviews including 12 studies addressing the question of this article, including five randomized controlled trials. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach...
September 15, 2016: Medwave
https://www.readbyqxmd.com/read/27688013/effects-of-the-single-and-combined-treatment-with-dopamine-agonist-somatostatin-analog-and-mtor-inhibitors-in-a-human-lung-carcinoid-cell-line-an-in-vitro-study
#19
Claudia Pivonello, Panagoula Rousaki, Mariarosaria Negri, Maddalena Sarnataro, Maria Napolitano, Federica Zito Marino, Roberta Patalano, Maria Cristina De Martino, Concetta Sciammarella, Antongiulio Faggiano, Gaetano Rocco, Renato Franco, Gregory A Kaltsas, Annamaria Colao, Rosario Pivonello
Somatostatin analogues and mTOR inhibitors have been used as medical therapy in lung carcinoids with variable results. No data are available on dopamine agonists as treatment for lung carcinoids. The main aim of the current study was to evaluate the effect of the combined treatment of somatostatin analogue octreotide and the dopamine agonist cabergoline with mTOR inhibitors in an in vitro model of typical lung carcinoids: the NCI-H727 cell line. In NCI-H727 cell line, reverse transcriptase-quantitative polymerase chain reaction and immunofluorescence were assessed to characterize the expression of the somatostatin receptor 2 and 5, dopamine receptor 2 and mTOR pathway components...
September 29, 2016: Endocrine
https://www.readbyqxmd.com/read/27678925/effect-of-cabergoline-in-experimental-endometriosis-in-rats
#20
J C Rosa-E-Silva, G G Fortunato, Jvc Zanardi, J Meola, A A Nogueira
No abstract text is available yet for this article.
November 2015: Journal of Minimally Invasive Gynecology
keyword
keyword
113789
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"